What are the common brand names of rhIL - 11 injection?
rhIL - 11 injection, or recombinant human interleukin - 11 injection, is a significant biopharmaceutical product with important applications in the medical field. As a supplier of rhIL - 11 injection, I am well - versed in the common brand names and the overall landscape of this product. In this blog, I will share some insights into the well - known brand names of rhIL - 11 injection, along with some related information about the product.
What is rhIL - 11 Injection?
Recombinant human interleukin - 11 is a cytokine that plays a crucial role in the regulation of hematopoiesis. It stimulates the growth of multiple hematopoietic cell lineages and promotes megakaryocyte maturation and platelet production. rhIL - 11 injection is mainly used to prevent severe thrombocytopenia (low platelet count) in patients receiving chemotherapy for non - myeloid malignancies. By increasing platelet levels, it helps reduce the need for platelet transfusions and associated complications.
Common Brand Names of rhIL - 11 Injection
There are several brand names of rhIL - 11 injection available in the market. One of the well - recognized brand names is Neumega. Neumega has been on the market for a long time and has established a good reputation among medical professionals. It has been widely used in clinical practice to manage thrombocytopenia induced by chemotherapy. The efficacy and safety of Neumega have been demonstrated in numerous clinical trials. The recommended dosage and administration of Neumega are based on the patient's condition and the type of chemotherapy they are undergoing.
Another brand that is also quite popular is Oprelvekin. Oprelvekin is a recombinant form of human interleukin - 11. It works by binding to specific receptors on hematopoietic progenitor cells, thereby promoting their proliferation and differentiation into megakaryocytes, which eventually produce platelets. Similar to Neumega, Oprelvekin is used to prevent and treat chemotherapy - induced thrombocytopenia. It has been shown to be effective in reducing the duration and severity of low platelet counts, which in turn decreases the risk of bleeding events in patients.
Comparison of Different Brands
When comparing different brand names of rhIL - 11 injection, several factors need to be considered. Efficacy is one of the most important aspects. Clinical studies have shown that both Neumega and Oprelvekin are effective in increasing platelet counts. However, the response rate may vary among individuals due to factors such as the patient's age, overall health status, and the type of chemotherapy they are receiving.
Safety is another crucial factor. Both brands have been associated with certain side effects. Common side effects of rhIL - 11 injection include fluid retention, which can lead to peripheral edema, shortness of breath, and tachycardia. Some patients may also experience cardiovascular side effects such as atrial arrhythmias. However, the incidence and severity of these side effects can vary between different brands and individual patients.
Cost is also an important consideration. The price of different brand names of rhIL - 11 injection can vary significantly. Pharmaceutical companies may offer different pricing strategies based on factors such as production costs, market competition, and research and development expenses. As a supplier, I understand the importance of providing cost - effective solutions to our customers while ensuring the quality and efficacy of the product.
Our Advantages as a Supplier
As a supplier of rhIL - 11 injection, we have several advantages. Firstly, we have a strict quality control system in place. We source our products from reliable manufacturers who adhere to strict Good Manufacturing Practices (GMP). This ensures that our rhIL - 11 injection meets the highest quality standards in terms of purity, potency, and stability.
Secondly, we offer a wide range of products. In addition to rhIL - 11 injection, we also supply other related pharmaceutical products. For example, we provide Daratumumab (with Recombinant Human Hyaluronidase)injection, CAS No.: 945721 - 28 - 8, which is used in the treatment of multiple myeloma. We also offer Fulvestrant– An Anti - cancer Drug ,CAS No.: 129453 - 61 - 8 for the treatment of breast cancer and Romosozumab Injection - Osteoporosis, CAS: 909395 - 70 - 6 for the treatment of osteoporosis. This allows our customers to source multiple products from a single supplier, which simplifies the procurement process.
Thirdly, we have a professional and experienced customer service team. Our team is dedicated to providing excellent customer service. We can answer all your questions regarding our products, including product specifications, dosage, administration, and potential side effects. We also offer customized solutions based on your specific needs.
The Future of rhIL - 11 Injection
The future of rhIL - 11 injection looks promising. With the continuous development of medical technology, there may be new formulations and delivery methods of rhIL - 11 injection in the future. For example, researchers are exploring the use of novel drug delivery systems to improve the bioavailability and targeted delivery of rhIL - 11. This could potentially enhance the efficacy of the product and reduce side effects.
In addition, the indication of rhIL - 11 injection may also expand. Currently, it is mainly used for chemotherapy - induced thrombocytopenia. However, there is ongoing research on its potential use in other areas, such as the treatment of bone marrow failure syndromes and the promotion of wound healing.
Contact Us for Procurement
If you are interested in purchasing rhIL - 11 injection or any of our other pharmaceutical products, we welcome you to contact us for further information and procurement discussions. We are committed to providing high - quality products and excellent service to our customers. Whether you are a hospital, a clinic, or a pharmaceutical distributor, we can offer you the best solutions to meet your needs.
References
- “Recombinant Human Interleukin - 11: A Review of Its Use in the Prevention of Chemotherapy - Induced Thrombocytopenia.” Journal of Clinical Oncology.
- Product information leaflets of Neumega and Oprelvekin.
- Clinical trials on the efficacy and safety of rhIL - 11 injection.